CommercialCoverageMedium impact
07.05.07e, Drug-Eluting Beads and Bland Embolization for the Treatment of Hepatic Malignancies
Independence Blue Cross·Radiology, Oncology, Pharmacy·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Policy 07.05.07e regarding Drug-Eluting Beads and Bland Embolization for hepatic malignancies was reissued effective October 29, 2025. This is a pharmacy/interventional policy affecting coverage and billing for hepatic embolization procedures. The billing team must review the full policy text to identify any changes to prior authorization requirements, covered procedures, or billing guidelines from the previous version.
Action Required
By November 15, 2025: Billing and clinical teams must obtain and review the complete policy text at https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-07-05-07e to identify specific changes from the previous version. Determine if changes affect: (1) prior authorization requirements for embolization procedures, (2) covered drug-eluting bead products and brands, (3) medical necessity criteria, or (4) billing codes. Update billing system rules, encounter forms, and provider documentation requirements accordingly. Alert interventional radiologists and interventional cardiologists of any coverage or authorization changes. Failure to implement required changes may result in claim denials or payment delays for hepatic embolization procedures.